Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.

PURPOSE Southwest Oncology Group (SWOG) protocol 8228 is a prospective trial designed to investigate the prognostic significance of progesterone receptor (PgR) levels in estrogen receptor (ER)-positive breast cancer patients who were treated with tamoxifen. This study was undertaken because the value of PgR measurements in advanced breast cancer had been assessed previously only in studies that were small, retrospective, or included heterogeneously treated patients. METHODS Receptor assays were performed only in the laboratories that met strict quality control guidelines. Of the 398 patients entered, 342 patients were eligible and assessable for the study end points of objective clinical response, time to treatment failure, and overall survival. RESULTS Multivariate analysis shows that elevated PgR levels significantly and independently correlated with increased probability of response to tamoxifen, longer time to treatment failure, and longer overall survival. Overall response rate (defined as complete response [CR], partial response [PR], or stable disease [SD] for greater than 6 months) in this trial was 54%. Response rates to tamoxifen were 43%, 53%, and 61% in subsets of patients with less than 10, 10 to 99, and more than 100 fmol/mg PgR, respectively. Exploratory subset analysis using PgR and other prognostic variables identified ER-positive patient subsets with response rates to tamoxifen ranging from 24% (premenopausal patients) to 86% (postmenopausal patients with ER greater than 38 and PgR greater than 329 fmol/mg). No groups of ER-positive patients were identified who had such a low response rate as to absolutely preclude considering the use of tamoxifen. Multivariate analysis showed the independent, statistically significant predictors were: for response to tamoxifen, menopausal status, PgR, and ER; for time to treatment failure, menopausal status, disease-free interval (DFI), PgR, and ER; and for overall survival DFI, PgR, ER, site of disease, and history of adjuvant therapy. CONCLUSION We conclude that knowledge of PgR levels together with other clinical information can improve the pretreatment assessment of ER-positive breast cancer patients with metastatic disease.

[1]  J. Garber,et al.  Comprehensive management of disseminated breast cancer , 1990, Cancer.

[2]  A. Paradiso,et al.  Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. , 1990, Cancer research.

[3]  P. Ravdin,et al.  Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. , 1988, Cancer research.

[4]  I. Ellis,et al.  Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. , 1987, British Journal of Cancer.

[5]  A. Howell,et al.  A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Pritchard,et al.  Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. , 1986, Cancer research.

[7]  J. Ingle,et al.  Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Osborne Ck.  Heterogeneity in hormone receptor status in primary and metastatic breast cancer. , 1985 .

[9]  R. Buchanan,et al.  A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. , 1984, British Journal of Cancer.

[10]  W. McGuire,et al.  Multiple progesterone receptor assays in human breast cancer. , 1984, Cancer research.

[11]  V. Vaitkevicius,et al.  Relation of tumor content of estrogen and progesteron receptors with response of patient to endocrine therapy , 1980, Cancer.

[12]  J. Daly,et al.  Correlation of estrogen and progesterone receptors with histologic differentiation in mammary carcinoma , 1980, Cancer.

[13]  L. Einhorn,et al.  Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer , 1980, Cancer.

[14]  Y. Nomura,et al.  Steroid hormone receptors and clinical usefulness in human breast cancer , 1980, Cancer.

[15]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.

[16]  N. Bloom,et al.  The role of progesterone receptors in the management of advanced breast cancer , 1980, Cancer.

[17]  Desombre Er.  Steroid receptors in breast cancer. , 1984, Monographs in pathology.

[18]  W. McGuire,et al.  Predicting response to endocrine therapy in human breast cancer: a hypothesis. , 1975, Science.

[19]  H. Ward.  Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels , 1973, British medical journal.

[20]  D. Cox,et al.  The analysis of binary data , 1971 .

[21]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[23]  W. McGuire,et al.  Variant human breast tumor estrogen receptor with constitutive transcriptional activity. , 1991, Cancer research.

[24]  Rutqvist Le.  The Significance of Hormone Receptors to Predict the Endocrine Responsiveness of Human Breast Cancer , 1990 .

[25]  A. Howell,et al.  Endocrine therapy for advanced carcinoma of the breast: effect of tumor heterogeneity and site of biopsy on the predictive value of progesterone receptor estimations. , 1987, Cancer research.

[26]  R. Rubens,et al.  Estrogen and progesterone receptors: Correlation of response rates, site and timing of receptor analysis , 1982, Breast cancer research and treatment.

[27]  D. Cox.  Regression Models and Life-Tables , 1972 .